Full Text Full Text (PDF) Data supplement Correction (v166,p731) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Articles by Davidson, M. Articles by Kahn, R. S. PubMed Citation Articles by Davidson, M. Articles by Kahn, R. S. Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders Related Article

Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)

OBJECTIVE: Cognitive impairment, manifested as mild to moderate deviations from psychometric norms, is present in many but not all schizophrenia patients. The purpose of the present study was to compare the effect of haloperidol with that of second-generation antipsychotic drugs on the cognitive performance of patients with schizophreniform disorder or first-episode schizophrenia. METHODS: Subjects were 498 patients with schizophreniform disorder or first-episode schizophrenia who were randomly assigned to open-label haloperidol (1 to 4 mg/day [N=103]), amisulpride (200 to 800 mg/day [N=104]), olanzapine (5 to 20 mg/day [N=105]), quetiapine (200 to 750 mg/day [N=104]), or ziprasidone (40 to 160 mg/day [N=82]). The Rey Auditory Verbal Learning Test, Trail Making Test Part A and Part B, WAIS Digit Symbol Test, and Purdue Pegboard Test were administered at baseline and the 6-month follow-up evaluation. RESULTS: Compared with scores at baseline, composite cognitive test scores improved for all five treatment groups at the 6-month follow-up evaluation. However, there were no overall differences among the treatment groups. In addition, there was a weak correlation between the degree of cognitive improvement and changes in Positive and Negative Syndrome Scale scores. CONCLUSION: Treatment with antipsychotic medication is associated with moderate improvement in the cognitive test performance of patients who have schizophreniform disorder or who are in their first episode of schizophrenia. The magnitude of improvement does not differ between treatment with haloperidol and treatment with second-generation antipsychotics. Moreover, cognitive improvement is weakly related to symptom change.

Related Article:

In This Issue
Am J Psychiatry 2009 166: A16. [Full Text] [PDF]

This article has been cited by other articles:

				E. Bora, M. Yucel, and C. Pantelis Cognitive Impairment in Schizophrenia and Affective Psychoses: Implications for DSM-V Criteria and Beyond Schizophr Bull, September 23, 2009; (2009) sbp094v1. [Abstract] [Full Text] [PDF]

				O. Robles, A. Zabala, I. Bombin, M. Parellada, D. Moreno, A. Ruiz-Sancho, and C. Arango Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis Schizophr Bull, August 25, 2009; (2009) sbp062v1. [Abstract] [Full Text] [PDF]

				T. E. Goldberg and J. J. Gomar Targeting Cognition in Schizophrenia Research: From Etiology to Treatment Am J Psychiatry, June 1, 2009; 166(6): 631 - 634. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us